Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Endocrinology›Condition·Updated Jul 2, 2026·v1

Type 1 Diabetes Mellitus

Type 1 diabetes mellitus is an autoimmune endocrine disorder characterized by absolute insulin deficiency from beta-cell destruction. Diagnosis relies on hyperglycemia plus low C-peptide and positive islet autoantibodies. Management centers on intensive insulin replacement (basal-bolus or pump) titrated to HbA1c <7.0%, augmented by CGM and advanced hybrid closed-loop systems to minimize hypoglycemia. DKA requires aggressive fluid resuscitation, IV insulin, and potassium replacement. Long-term outcomes have improved dramatically since the DCCT, but microvascular and macrovascular complications remain significant; annual screening for retinopathy, nephropathy, and neuropathy is essential. First-degree relatives should be offered autoantibody screening in research settings. The FDA approval of teplizumab marks the first disease-modifying therapy, offering the potential to delay clinical onset in high-risk individuals.

High Evidence243 references·4,744 words·19 min read·v1
type 1 diabetesautoimmune diabetesinsulin deficiencydiabetic ketoacidosisC-peptideislet autoantibodiesbasal-bolus insulincontinuous glucose monitoringhybrid closed-loopDCCT

Quick Reference

RxDrug of choiceInsulin degludec (basal) 0.2-0.4 U/kg once daily plus insulin aspart (prandial) 0.05-0.15 U/kg per meal
AltAlternativesInsulin glargine U100 0.2-0.4 U/kg once daily; insulin lispro or glulisine for prandial coverage; insulin pump (CSII) with rapid-acting analogue; advanced hybrid closed-loop (AHCL) system
⊘AvoidSGLT2 inhibitors (dapagliflozin, empagliflozin) outside clinical trials due to DKA risk; non-dihydropyridine CCBs (diltiazem, verapamil); NPH insulin as first-line if analogue available (higher nocturnal hypoglycemia)
DxTest of choiceC-peptide (fasting <0.2 nmol/L or stimulated <0.6 nmol/L) plus islet autoantibody panel (GADA, IA-2A, ZnT8A) to confirm autoimmune T1DM
ScKey scoreADA staging: Stage 1 (≥2 autoantibodies, normoglycemia), Stage 2 (autoantibodies + dysglycemia), Stage 3 (clinical diabetes); HbA1c target <7.0%
→When to referDKA with pH <7.0 or altered mental status (ICU); recurrent severe hypoglycemia despite optimized therapy (consider pancreas/islet transplant); pregnancy for preconception counseling; antibody-negative diabetes with suspected monogenic cause (genetic testing)
T1DM requires lifelong basal-bolus insulin replacement titrated to HbA1c <7.0% with CGM to maximize time-in-range and minimize hypoglycemia; DKA management follows a protocol of fluid resuscitation, IV insulin, and potassium replacement without routine bicarbonate.
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune endocrine disorder characterized by absolute insulin deficiency from progressive pancreatic beta-cell destruction. It accounts for 5-10% of all diabetes, most common in children and adolescents. Acute complications include diabetic ketoacidosis (DKA) and severe hypoglycemia; chronic complications include retinopathy, nephropathy, neuropathy, and accelerated cardiovascular disease. Early recognition and intensive insulin therapy are critical to reduce morbidity and mortality.

Overview and Recommendations

Background

  • •Type 1 diabetes mellitus (T1DM), absolute insulin deficiency from autoimmune beta-cell destruction, affects approximately 1.45 million people in the United States, with a global incidence rising 3-4% per year, a pace too rapid for genetic drift alone.
  • •The disease follows a predictable staging paradigm: Stage 1 (≥2 islet autoantibodies, normoglycemia), Stage 2 (autoantibodies plus dysglycemia), and Stage 3 (symptomatic hyperglycemia). Progression from Stage 1 to clinical diabetes occurs in >70% of individuals over 5 years.
  • •The autoimmune attack targets well-characterized beta-cell antigens: GAD65 (glutamic acid decarboxylase), IA-2 (insulinoma-associated protein 2), ZnT8 (zinc transporter 8), and insulin. CD8+ cytotoxic T-cells mediate destruction via perforin/granzyme and Fas-FasL pathways.
  • •Genetic susceptibility is dominated by HLA class II haplotypes DR3-DQ2 and DR4-DQ8 (OR >20 for heterozygotes), with additional risk from non-HLA loci including PTPN22, INS, CTLA4, and IL2RA. Environmental triggers, most consistently enteroviral infection, initiate or accelerate autoimmunity in genetically predisposed individuals.

Evaluation

  • •Suspect T1DM in any patient with polyuria, polydipsia, unintentional weight loss (5-10% over weeks), fatigue, blurred vision, or new-onset nocturnal enuresis in children.
  • •Ask about the duration of symptoms, classic T1DM progresses over 2-6 weeks in children and adolescents; adults may have a more insidious course over months.
  • •Ask about family history of T1DM (RR 15 for first-degree relatives), other autoimmune diseases (thyroid, celiac, Addison's), and recent viral illness.
  • •Examine for signs of dehydration (dry mucous membranes, reduced skin turgor, tachycardia), Kussmaul respirations, acetone breath, and altered mental status indicating DKA.
  • •Order STAT fingerstick blood glucose and urine or serum ketones (beta-hydroxybutyrate) in any symptomatic patient.
  • •Confirm diabetes with fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%.
  • •Assess for DKA using the triad: glucose >250 mg/dL, venous pH <7.3, serum bicarbonate <15 mEq/L, and positive ketones.
  • •Measure C-peptide (fasting or stimulated) to distinguish T1DM from type 2 diabetes: fasting C-peptide <0.2 nmol/L (<0.6 ng/mL) confirms absolute insulin deficiency.
  • •Order islet autoantibody panel (GADA, IA-2A, ZnT8A), ≥1 positive confirms autoimmune etiology; panel sensitivity is 85-90% at diagnosis.
  • •If autoantibodies are negative, consider genetic testing for monogenic diabetes (WFS1, INS, GCK, HNF1A, HNF4A), especially in young children or those with family history.
  • •Screen for associated autoimmune diseases at diagnosis: TSH and TPO antibodies (autoimmune thyroid disease in 15-30% of T1DM), tissue transglutaminase IgA (tTG-IgA) for celiac disease.
  • •In a patient with DKA, assess severity by venous pH (mild pH 7.25-7.30, moderate pH 7.00-7.24, severe pH <7.00) and triage to appropriate level of care.
  • •Use an algorithm for antibody-negative cases: if C-peptide low, consider idiopathic T1DM or monogenic diabetes; if C-peptide normal/high, consider type 2 diabetes or MODY.

Management

  • •Initiate insulin therapy immediately once T1DM is confirmed. Start basal-bolus regimen at total daily dose (TDD) of 0.5-1.0 U/kg/day.
  • •Administer 50% of TDD as basal insulin, insulin degludec (0.2-0.4 U/kg once daily), glargine U100 (0.2-0.4 U/kg once daily), or glargine U300 (0.3-0.5 U/kg once daily). Degludec reduces nocturnal hypoglycemia vs glargine (rate ratio 0.75, 95% CI 0.59-0.96).
  • •Administer 50% of TDD as prandial rapid-acting analogue (lispro, aspart, glulisine) at 0.05-0.15 U/kg per meal, adjusted for carbohydrate content and premeal glucose.
  • •For DKA: fluid resuscitation with 0.9% normal saline 15-20 mL/kg over first hour (1 L in adults), then 250-500 mL/h. Replace half the deficit over 8 hours.
  • •For DKA: after fluids, give regular insulin 0.1 U/kg IV bolus, then 0.1 U/kg/h continuous IV infusion. Do not start insulin if K+ <3.3 mEq/L, replete potassium first.
  • •When blood glucose falls to 250 mg/dL, add 5% dextrose to IV fluids and reduce insulin to 0.05-0.1 U/kg/h to maintain glucose 150-200 mg/dL until acidosis resolves.
  • •Replace potassium when serum K+ <5.3 mEq/L: add 20-30 mEq potassium chloride or phosphate per liter IV fluid, target K+ 4-5 mEq/L. Monitor every 2 hours.
  • •Reserve bicarbonate for pH <6.9: give 50-100 mEq NaHCO₃ in 200 mL sterile water over 30-60 minutes with ECG monitoring. Do not use routinely.
  • •Transition from IV to subcutaneous insulin only after DKA resolves (anion gap <12 mEq/L, pH >7.3). Overlap IV and SC insulin by 1-2 hours.
  • •Titrate all patients to HbA1c <7.0% (<53 mmol/mol) for most nonpregnant adults; target <7.5% for children and adolescents to balance hypoglycemia risk.
  • •Prescribe continuous glucose monitoring (CGM) for all patients with T1DM, reduces severe hypoglycemia by 40-50% and improves HbA1c by 0.3-0.5% in adults ≥25 years.
  • •Advanced hybrid closed-loop systems (MiniMed 780G, Tandem Control-IQ) are recommended as preferred therapy, achieve time-in-range >70% with reduced hypoglycemia.
  • •For severe hypoglycemia (unconscious or unable to swallow): give glucagon 1 mg IM or intranasal 3 mg, or IV dextrose 50% 25 g. Recheck in 15 minutes.
  • •For conscious hypoglycemia (<70 mg/dL): administer 15-20 g oral glucose (4 oz juice, 3-4 glucose tablets); repeat in 15 minutes if still <70 mg/dL.
  • •Anticoagulate with statins in all patients aged ≥40 years, or younger with LDL ≥100 mg/dL, hypertension, smoking, or family history of premature CVD. Target LDL <70 mg/dL.
  • •Add ACE inhibitor or ARB when urinary albumin-to-creatinine ratio (UACR) >30 mg/g, regardless of blood pressure, to slow nephropathy progression.
  • •Do not use SGLT2 inhibitors as routine adjunct, 3.5-fold increased DKA risk (NNH = 28) and FDA boxed warning; consider only in clinical trials.
  • •Do not use non-dihydropyridine CCBs (diltiazem, verapamil), they exacerbate heart failure in diabetic cardiomyopathy.
  • •Do not omit basal insulin during illness or fasting, this is the most common precipitant of DKA. Increase insulin by 20-50% during intercurrent illness.

Board Review — High Yield

  • •DCCT/EDIC study, intensive insulin therapy (HbA1c ~7%) reduces retinopathy by 76%, nephropathy by 54%, CVD by 42%; legacy effect persists for decades despite later HbA1c convergence.
  • •C-peptide <0.2 nmol/L, distinguishes T1DM (absolute deficiency) from T2DM with high specificity; stimulated C-peptide <0.6 nmol/L confirms severe beta-cell loss.
  • •GADA, IA-2A, ZnT8A, ≥1 positive confirms autoimmune etiology; ZnT8A useful in antibody-negative cases and may signal concurrent autoimmune thyroiditis.
  • •HLA DR3-DQ2 and DR4-DQ8, strongest genetic risk (OR >20 for heterozygotes); non-HLA loci (PTPN22, INS, CTLA4) contribute modest additive risk.
  • •DKA triad, glucose >250 mg/dL, pH <7.3, bicarbonate <15 mEq/L with ketones; treatment: NS 15-20 mL/kg, IV insulin 0.1 U/kg bolus + 0.1 U/kg/h, K+ replacement.
  • •DO NOT use bicarbonate for DKA unless pH <6.9, no outcome benefit, may worsen hypokalemia and cerebral edema.
  • •Advanced hybrid closed-loop (AHCL), preferred therapy; MiniMed 780G and Tandem Control-IQ achieve TIR >70% with fewer hypoglycemic events vs MDI.
  • •SGLT2i contraindicated in T1DM, 3.5-fold DKA risk (NNH 28); avoid outside clinical trials despite HbA1c reduction of 0.37%.
  • •Autoimmune polyglandular syndrome type 2, Addison disease + T1DM or thyroid disease; screen with TSH, TPO antibodies, tTG-IgA at diagnosis; annual TSH thereafter.
  • •Teplizumab (anti-CD3), first FDA-approved disease-modifying therapy; delays progression from Stage 2 to Stage 3 T1DM by ~2 years in at-risk individuals.

Deep Dive — Evidence Details

References

  1. [1]

    Dost A, Bechtold S, Fink K et al.. “2017 American Academy of Pediatrics Clinical Practice Guideline: Impact on Prevalence of Arterial Hypertension in Children and Adolescents With Type 1 Diabetes.” Diabetes care (2020). PMID: 32229598 ↗

    L2GUIDELINECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  2. [2]

    de Vries M, Westerink J, Kaasjager KHAH et al.. “Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32827432 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  3. [3]

    Wada E, Onoue T, Kinoshita T et al.. “Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study.” Diabetologia (2021). PMID: 34268631 ↗

    L3COHORTCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation
  4. [4]

    Shaka H, Aguilera M, Aucar M et al.. “Rate and Predictors of 30-day Readmission Following Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A US Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34043791 ↗

    L2OTHERCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  5. [5]

    Amato MC, Guarnotta V, Ciresi A et al.. “No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24243639 ↗

    L3OTHERCited in: Definition, Classification and Axis Nomenclature
  6. [6]

    Codner E, Soto N, Lopez P et al.. “Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16569737 ↗

    L3OTHERCited in: Definition, Classification and Axis Nomenclature
  7. [7]

    Leslie RD, Palmer J, Schloot NC et al.. “Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.” Diabetologia (2016). PMID: 26498592 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  8. [8]

    Marques-Couto P, Afonso J, Coelho-Costa I et al.. “Prevalence and Risk Factors of Diabetic Macular Edema in Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Ophthalmology. Retina (2025). PMID: 41016555 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
  9. [9]

    Weissmann S, Amitai N, Honig E et al.. “Maternal type 1 diabetes mellitus and atopic dermatitis in offspring: A nationwide cohort study.” JAAD international (2026). PMID: 42100114 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
  10. [10]

    Kim KJ, Kim S, Oh R et al.. “High Waist-to-Height Ratio Increases the Risk of Cardiovascular Outcomes in Adults with Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2025). PMID: 40904015 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature
  11. [11]

    Weng SS, Chien LY. “IVF and risk of Type 1 diabetes mellitus: a population-based nested case-control study.” Human reproduction (Oxford, England) (2024). PMID: 38852062 ↗

    L3CASE_CONTROLCited in: Definition, Classification and Axis Nomenclature
  12. [12]

    Tetik Dinçer B, Urgancı N, Koç A et al.. “Association of endocrine autoantibodies (anti-TPO, anti-GAD, anti-insulin) with histopathological severity in pediatric Celiac disease: a retrospective cohort study.” BMC pediatrics (2025). PMID: 41430660 ↗

    L3COHORTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  13. [13]

    Zan Y, Wei Y, Zhang W et al.. “Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review.” Medicine (2025). PMID: 40388765 ↗

    L4SR_OBSCited in: Definition, Classification and Axis Nomenclature
  14. [14]

    Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40652453 ↗

    L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  15. [15]

    Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” European journal of endocrinology (2025). PMID: 40652450 ↗

    L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  16. [16]

    Pozzilli P, Bosi E, Cirkel D et al.. “Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32219329 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
  17. [17]

    Pescovitz MD, Greenbaum CJ, Bundy B et al.. “B-lymphocyte depletion with rituximab and β-cell function: two-year results.” Diabetes care (2013). PMID: 24026563 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  18. [18]

    Codner E, Escobar-Morreale HF. “Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17284617 ↗

    L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  19. [19]

    Du M, Basu A, Fu D et al.. “Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study.” Diabetes care (2013). PMID: 23393212 ↗

    L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
  20. [20]

    de Filette JMK, Pen JJ, Decoster L et al.. “Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.” European journal of endocrinology (2019). PMID: 31330498 ↗

    L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  21. [21]

    Geddes J, Deary IJ, Frier BM. “Effects of acute insulin-induced hypoglycaemia on psychomotor function: people with type 1 diabetes are less affected than non-diabetic adults.” Diabetologia (2008). PMID: 18709352 ↗

    L1TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies
  22. [22]

    Clotman K, Janssens K, Specenier P et al.. “Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29955867 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  23. [23]

    Morkos M, Nensey NK, Bindal A. “Micafungin-Induced Hypoglycemia in a Patient With Type 1 Diabetes: A Case Report and Review of Literature.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398618 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  24. [24]

    Yoneda S, Imagawa A, Fukui K et al.. “A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28398495 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  25. [25]

    Fazeli PK, Horowitz MC, MacDougald OA et al.. “Marrow fat and bone--new perspectives.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23393168 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  26. [26]

    Tomar N, Gupta N, Goswami R. “Calcium-sensing receptor autoantibodies and idiopathic hypoparathyroidism.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23873991 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  27. [27]

    Hough FS, Pierroz DD, Cooper C et al.. “MECHANISMS IN ENDOCRINOLOGY: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus.” European journal of endocrinology (2015). PMID: 26537861 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  28. [28]

    Verrotti A, Scaparrotta A, Olivieri C et al.. “Seizures and type 1 diabetes mellitus: current state of knowledge.” European journal of endocrinology (2012). PMID: 22956556 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  29. [29]

    Kratzsch J, Knerr I, Galler A et al.. “Metabolic decompensation in children with type 1 diabetes mellitus associated with increased serum levels of the soluble leptin receptor.” European journal of endocrinology (2006). PMID: 16990661 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  30. [30]

    Assmann TS, Brondani Lde A, Bauer AC et al.. “Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus.” European journal of endocrinology (2014). PMID: 24408902 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  31. [31]

    Jobanputra R, Sargeant JA, Plekhanova T et al.. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/metabolism research and reviews (2026). PMID: 42319968 ↗

    L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  32. [32]

    Frandsen CS, Dejgaard TF, Madsbad S. “Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.” The lancet. Diabetes & endocrinology (2016). PMID: 26969516 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  33. [33]

    Elliott J, Sloan G, Stevens L et al.. “Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study.” Diabetologia (2023). PMID: 37870649 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  34. [34]

    Korczak DJ, Pereira S, Koulajian K et al.. “Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link.” Diabetologia (2011). PMID: 21789690 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification
  35. [35]

    Pane JA, Coulson BS. “Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes.” Diabetologia (2015). PMID: 25794781 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  36. [36]

    Roca-Rivada A, Marín-Cañas S, Colli ML et al.. “Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death.” Diabetologia (2023). PMID: 36988639 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  37. [37]

    Nieuwdorp M, Holleman F, de Groot E et al.. “Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis.” Diabetologia (2007). PMID: 17415544 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  38. [38]

    Segev Y, Eshet R, Yakir O et al.. “Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes.” Diabetologia (2007). PMID: 17443310 ↗

    L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  39. [39]

    Kateel R, Parida A, Chogtu B et al.. “Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42105869 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies
  40. [40]

    Abdel-Rahman SM, Al-Shiab R, Shah E et al.. “Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.” Diabetes, obesity & metabolism (2026). PMID: 41605813 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  41. [41]

    Rivetti G, Braile M, Di Sessa A et al.. “Acute Kidney Injury in Children with Polyuria: A Systematic Review.” Journal of clinical medicine (2026). PMID: 41517599 ↗

    L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  42. [42]

    Jawad M, Afaq S, Hussain S et al.. “Effect of digital interventions on adherence to the management of type 1 diabetes mellitus patients: a systematic review.” BMC endocrine disorders (2025). PMID: 41462455 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  43. [43]

    Chen Y, Tang Y, Yue R et al.. “Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41331723 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  44. [44]

    Biondi B, Kahaly GJ, Robertson RP. “Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders.” Endocrine reviews (2019). PMID: 30649221 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  45. [45]

    Meijnikman AS, Gerdes VE, Nieuwdorp M et al.. “Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans.” Endocrine reviews (2018). PMID: 29309555 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  46. [46]

    Rotondi M, Chiovato L, Romagnani S et al.. “Role of chemokines in endocrine autoimmune diseases.” Endocrine reviews (2007). PMID: 17475924 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  47. [47]

    Hbibi M, Elamine A, Benhsaien I et al.. “Case Report: Different faces of LRBA deficiency in five Moroccan families.” Frontiers in immunology (2026). PMID: 42148132 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  48. [48]

    Al Hayek A, Robert AA, Al Burayk AK et al.. “Comparative Clinical and Metabolic Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 1 Diabetes: A Retrospective Cohort Study from Saudi Arabia.” Current diabetes reviews (2026). PMID: 41691684 ↗

    L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  49. [49]

    Horton WB, Snell-Bergeon JK. “Hemoglobin A1c Variability Metrics Predict Coronary Artery Calcium and Cardiovascular Events in Type 1 Diabetes: The CACTI Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36637994 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  50. [50]

    Tsaitlin-Mor L, Cahen-Peretz A, Bentov Y et al.. “Long-term Risk for Type 1 Diabetes and Obesity in Early Term Born Offspring: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38079466 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
  51. [51]

    Balsells M, García-Patterson A, Gich I et al.. “Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19808847 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  52. [52]

    Nicholson WK, Robinson KA, Smallridge RC et al.. “Prevalence of postpartum thyroid dysfunction: a quantitative review.” Thyroid : official journal of the American Thyroid Association (2006). PMID: 16839259 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  53. [53]

    Aslam AA, Baksh RA, Pape SE et al.. “Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records.” Diabetes care (2022). PMID: 36178378 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  54. [54]

    Zhong VW, Juhaeri J, Cole SR et al.. “Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2017). PMID: 28716781 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
  55. [55]

    Drenthen LCA, Ajie M, Abbink EJ et al.. “No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study.” Diabetologia (2023). PMID: 36879098 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  56. [56]

    Bo S, Gentile L, Castiglione A et al.. “C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.” European journal of endocrinology (2012). PMID: 22577110 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  57. [57]

    Morgan E, Halliday SR, Campbell GR et al.. “Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2015). PMID: 26564178 ↗

    L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  58. [58]

    de Vries SAG, Verheugt CL, Mul D et al.. “Do sex differences in paediatric type 1 diabetes care exist? A systematic review.” Diabetologia (2023). PMID: 36700969 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  59. [59]

    Jeitler K, Horvath K, Berghold A et al.. “Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.” Diabetologia (2008). PMID: 18351320 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  60. [60]

    Cardwell CR, Stene LC, Joner G et al.. “Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2008). PMID: 18292986 ↗

    L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  61. [61]

    Stagnaro-Green A. “Approach to the patient with postpartum thyroiditis.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22312089 ↗

    L5CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  62. [62]

    Chou IC, Wang CH, Lin WD et al.. “Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study.” Diabetologia (2016). PMID: 27030312 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  63. [63]

    Dafoulas GE, Toulis KA, Mccorry D et al.. “Type 1 diabetes mellitus and risk of incident epilepsy: a population-based, open-cohort study.” Diabetologia (2016). PMID: 27796422 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  64. [64]

    Mikłosz A, Chabowski A. “Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36916961 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  65. [65]

    Li FR, Hukportie DN, Yang J et al.. “Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes.” Diabetes care (2022). PMID: 35944243 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors
  66. [66]

    Chen X, Affinati AH, Lee Y et al.. “Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.” Diabetes care (2022). PMID: 35238899 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  67. [67]

    Jacobson AM, Braffett BH, Erus G et al.. “Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study.” Diabetes care (2022). PMID: 35699949 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications and Long-term Sequelae
  68. [68]

    Tamer G, Arik S, Tamer I et al.. “Relative vitamin D insufficiency in Hashimoto's thyroiditis.” Thyroid : official journal of the American Thyroid Association (2011). PMID: 21751884 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors
  69. [69]

    Denzer C, Karges B, Näke A et al.. “Subclinical hypothyroidism and dyslipidemia in children and adolescents with type 1 diabetes mellitus.” European journal of endocrinology (2013). PMID: 23384709 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  70. [70]

    Sahakyan K, Klein BE, Lee KE et al.. “Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus.” European journal of endocrinology (2010). PMID: 20332124 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors
  71. [71]

    Chantzichristos D, Persson A, Eliasson B et al.. “Incidence, prevalence and seasonal onset variation of Addison's disease among persons with type 1 diabetes mellitus: nationwide, matched cohort studies.” European journal of endocrinology (2017). PMID: 29066573 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  72. [72]

    Okosieme OE, Wijeyaratne CN, Lazarus JH et al.. “Restricted thyroglobulin antibody epitope specificities in subjects with type 1 diabetes mellitus.” European journal of endocrinology (2009). PMID: 19561043 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors
  73. [73]

    Pappa A, Koromantzos P, Seremidi K et al.. “Dental caries and periodontal status in children and adolescents with type 1 diabetes mellitus: an umbrella review.” European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry (2026). PMID: 42270944 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  74. [74]

    Anesini MB, Pinto M, Bellezza M et al.. “Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review.” Journal of clinical medicine (2026). PMID: 42123251 ↗

    L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  75. [75]

    Shao MM, Scheideman AF, Zhou AM et al.. “Accuracy of glutamic acid decarboxylase antibodies for the identification of adult-onset type 1 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987896 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  76. [76]

    Di Gialleonardo V, de Vries EF, Di Girolamo M et al.. “Imaging of β-cell mass and insulitis in insulin-dependent (Type 1) diabetes mellitus.” Endocrine reviews (2012). PMID: 22889646 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
  77. [77]

    Mackay L, Kilbride L, Adamson KA et al.. “Hormone replacement therapy for women with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2013). PMID: 23744560 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  78. [78]

    Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2013). PMID: 23543528 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  79. [79]

    Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2006). PMID: 17054193 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  80. [80]

    Callaghan BC, Little AA, Feldman EL et al.. “Enhanced glucose control for preventing and treating diabetic neuropathy.” The Cochrane database of systematic reviews (2012). PMID: 22696371 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
  81. [81]

    Montero N, Webster AC, Royuela A et al.. “Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.” The Cochrane database of systematic reviews (2014). PMID: 25220222 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention
  82. [82]

    Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗

    L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
  83. [83]

    Singh M, Subramanian A, Wambua S et al.. “Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK.” BMC medicine (2026). PMID: 42169116 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  84. [84]

    Gatira DN, Getnet M, Liyew B et al.. “Incidence and predictors of diabetic ketoacidosis among adults with type 1 diabetes in Northwest, Ethiopia, 2023: a retrospective cohort study.” BMC public health (2026). PMID: 41957727 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Complications and Long-term Sequelae
  85. [85]

    Halpern B, Nery M, Pereira MAA. “Case Report of Acquired Generalized Lipodystrophy Associated With Common Variable Immunodeficiency.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29846625 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  86. [86]

    Aly HH, Fouda EM, Kotby AA et al.. “COVID-19-Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series.” Diabetes care (2022). PMID: 35113159 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  87. [87]

    Dunn A, Lam A, Hidalgo L et al.. “Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398662 ↗

    L4OTHERCited in: Clinical Presentation
  88. [88]

    Schreiner F, Plamper M, Dueker G et al.. “Infancy-Onset T1DM, Short Stature, and Severe Immunodysregulation in Two Siblings With a Homozygous LRBA Mutation.” The Journal of clinical endocrinology and metabolism (2016). PMID: 26745254 ↗

    L4OTHERCited in: Clinical Presentation
  89. [89]

    Johnson SR, Carter HE, Leo P et al.. “Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life.” Diabetes care (2018). PMID: 30523035 ↗

    L2OTHERCited in: Clinical Presentation, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  90. [90]

    Tsai EB, Sherry NA, Palmer JP et al.. “The rise and fall of insulin secretion in type 1 diabetes mellitus.” Diabetologia (2006). PMID: 16404554 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
  91. [91]

    Aparna KV, Darshan M, Kulkarni A et al.. “Emphysematous pyelonephritis in children: Lessons from a case report and systematic review.” Journal of pediatric urology (2026). PMID: 42285016 ↗

    L4SR_OBSCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  92. [92]

    Alqahtani YA, Shati AA, Alshaikh AA et al.. “Prevalence and Recovery of Euthyroid Sick Syndrome in Pediatric Diabetic Ketoacidosis: A Retrospective Cohort Study.” Children (Basel, Switzerland) (2026). PMID: 41749652 ↗

    L2COHORTCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  93. [93]

    Li X, Zhang X, Dai X et al.. “Proliferative glomerulonephritis with monoclonal immunoglobulin IgG1-κ deposition in a patient with type 1 diabetes: a case report and literature review.” Frontiers in medicine (2026). PMID: 42375207 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  94. [94]

    Bai H, Yu J, Wang T et al.. “Case Report: A novel likely pathogenic GCK variant in a young Chinese girl with severe insulin resistance.” Frontiers in endocrinology (2026). PMID: 42137361 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  95. [95]

    Liu S, Cao C, Wang X. “Autoimmune polyglandular syndrome type 1 with compound heterozygous AIRE gene pathogenic variants and stage 1 type 1 diabetes mellitus: case report and literature review of Chinese population.” Frontiers in immunology (2026). PMID: 41993177 ↗

    L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment
  96. [96]

    Valdivia Camacho OD, Allison T, Wilson LB et al.. “Pediatric Cataracts as a Presenting Sign of Type 1 Diabetes Mellitus.” The Journal of pediatrics (2025). PMID: 40945580 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  97. [97]

    Maruyama T, Tanaka S, Shimada A et al.. “Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18397986 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
  98. [98]

    Matejko B, Juza A, Kieć-Wilk B et al.. “Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.” Diabetes care (2022). PMID: 35972259 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  99. [99]

    Luijf YM, DeVries JH, Zwinderman K et al.. “Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management.” Diabetes care (2013). PMID: 24170747 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  100. [100]

    Ma X, Xie Z, Qin J et al.. “Association of Vitamin D Pathway Gene CYP27B1 and CYP2R1 Polymorphisms with Autoimmune Endocrine Disorders: A Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32915988 ↗

    L3SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  101. [101]

    Ludvigsson J, Faresjö M, Hjorth M et al.. “GAD treatment and insulin secretion in recent-onset type 1 diabetes.” The New England journal of medicine (2008). PMID: 18843118 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  102. [102]

    Tamborlane WV, Beck RW, Bode BW et al.. “Continuous glucose monitoring and intensive treatment of type 1 diabetes.” The New England journal of medicine (2008). PMID: 18779236 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  103. [103]

    Ludvigsson J, Krisky D, Casas R et al.. “GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.” The New England journal of medicine (2012). PMID: 22296077 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  104. [104]

    Zhong VW, Juhaeri J, Mayer-Davis EJ. “Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2018). PMID: 29386248 ↗

    L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  105. [105]

    Szypowska A, Ramotowska A, Dzygalo K et al.. “Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials.” European journal of endocrinology (2011). PMID: 22096111 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
  106. [106]

    Teo E, Hassan N, Tam W et al.. “Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis.” Diabetologia (2022). PMID: 35141761 ↗

    L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
  107. [107]

    Orban T, Bundy B, Becker DJ et al.. “Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2011). PMID: 21719096 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  108. [108]

    Schultz ANØ, Christensen R, Bollig G et al.. “Effectiveness of video consultations in type 1 diabetes patients treated with insulin pumps in the outpatient clinic: a randomised controlled trial.” Diabetologia (2025). PMID: 41198916 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  109. [109]

    Benhalima K, van Nes F, Laenen A et al.. “Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.” Diabetologia (2021). PMID: 34647140 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
  110. [110]

    Gejl M, Gjedde A, Brock B et al.. “Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial.” Diabetologia (2017). PMID: 29188338 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
  111. [111]

    Golicki DT, Golicka D, Groele L et al.. “Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis.” Diabetologia (2007). PMID: 18060380 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  112. [112]

    Goldacre RR. “Associations between birthweight, gestational age at birth and subsequent type 1 diabetes in children under 12: a retrospective cohort study in England, 1998-2012.” Diabetologia (2017). PMID: 29128935 ↗

    L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  113. [113]

    De Meulemeester J, Keymeulen B, De Block C et al.. “One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.” Diabetologia (2025). PMID: 39934368 ↗

    L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  114. [114]

    Yapanis M, James S, Craig ME et al.. “Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35094087 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  115. [115]

    Shalimova A, Graff B, Gąsecki D et al.. “Cognitive Dysfunction in Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30657922 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae
  116. [116]

    Prinz N, Tittel SR, Bachran R et al.. “Characteristics of Patients with Type 1 Diabetes and Additional Autoimmune Disease in the DPV Registry.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34061946 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  117. [117]

    Wang Y, Qin Y, Gu H et al.. “High Residual β-cell Function in Chinese Patients With Autoimmune Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35218654 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  118. [118]

    Menon JC, Singh P, Archana A et al.. “High Frequency of Recessive WFS1 Mutations Among Indian Children With Islet Antibody-negative Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37931151 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  119. [119]

    Ling P, Yang D, Wang C et al.. “Basal Hyperglycemia Contributes More Than 50% to Time in Range in Pregnant Women With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38686666 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  120. [120]

    Demmer RT, Holtfreter B, Desvarieux M et al.. “The influence of type 1 and type 2 diabetes on periodontal disease progression: prospective results from the Study of Health in Pomerania (SHIP).” Diabetes care (2012). PMID: 22855731 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  121. [121]

    Barrett CE, Park J, Kompaniyets L et al.. “Intensive Care Unit Admission, Mechanical Ventilation, and Mortality Among Patients With Type 1 Diabetes Hospitalized for COVID-19 in the U.S.” Diabetes care (2021). PMID: 34158365 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  122. [122]

    Epstein EJ, Osman JL, Cohen HW et al.. “Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes.” Diabetes care (2013). PMID: 23596179 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  123. [123]

    Scheuing N, Bartus B, Berger G et al.. “Clinical characteristics and outcome of 467 patients with a clinically recognized eating disorder identified among 52,215 patients with type 1 diabetes: a multicenter german/austrian study.” Diabetes care (2014). PMID: 24623022 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  124. [124]

    van Elderen SG, Brandts A, van der Grond J et al.. “Cerebral perfusion and aortic stiffness are independent predictors of white matter brain atrophy in type 1 diabetic patients assessed with magnetic resonance imaging.” Diabetes care (2011). PMID: 21216862 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  125. [125]

    Lundgaard AT, Westergaard D, Röder T et al.. “Longitudinal metabolite and protein trajectories prior to diabetes mellitus diagnosis in Danish blood donors: a nested case-control study.” Diabetologia (2024). PMID: 39078488 ↗

    L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  126. [126]

    Aleksova J, Ebeling PR, Milat F et al.. “DXA-derived advanced hip analysis and the trabecular bone score in end-stage kidney disease secondary to type 1 diabetes.” European journal of endocrinology (2022). PMID: 36315195 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  127. [127]

    Martos-Moreno GA, Barrios V, Soriano-Guillén L et al.. “Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy.” European journal of endocrinology (2006). PMID: 17062893 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  128. [128]

    Faccinetti NI, Guerra LL, Penas Steinhardt A et al.. “Characterization of zinc transporter 8 (ZnT8) antibodies in autoimmune diabetic patients from Argentinian population using monomeric, homodimeric, and heterodimeric ZnT8 antigen variants.” European journal of endocrinology (2015). PMID: 26567119 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  129. [129]

    Rogowicz-Frontczak A, Zozuliłska-Ziołkiewicz D, Litwinowicz M et al.. “Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes?” European journal of endocrinology (2014). PMID: 24480135 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
  130. [130]

    Krassas GE, Tziomalos K, Pontikides N et al.. “Seasonality of month of birth of patients with Graves' and Hashimoto's diseases differ from that in the general population.” European journal of endocrinology (2007). PMID: 17535862 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  131. [131]

    Lin Q, Zhou Y, Lei M et al.. “Efficacy and safety of automated insulin delivery system in very young children with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42108409 ↗

    L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  132. [132]

    Murray JA, Husby S. “Celiac Disease.” The New England journal of medicine (2026). PMID: 41950475 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  133. [133]

    Langendam M, Luijf YM, Hooft L et al.. “Continuous glucose monitoring systems for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 22258980 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  134. [134]

    Clar C, Waugh N, Thomas S. “Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17443539 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  135. [135]

    Mărgineanu C, Usatiuc LO, Sur ML et al.. “The Bidirectional Relationship Between Type 1 Diabetes Mellitus and Obesity in Pediatric Patients: A Systematic Review.” Children (Basel, Switzerland) (2026). PMID: 42353914 ↗

    L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  136. [136]

    Ma IH, Huang WL, Liu YL et al.. “Early Retinal Changes Detected Using Optical Coherence Tomography Angiography in Youth with Type 1 Diabetes Mellitus: A Case-Control Study.” Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (2026). PMID: 41984745 ↗

    L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  137. [137]

    Harada K, Okazaki Y, Ichiba T. “Prehospital identification of hypoglycemia-induced seizure using a smartphone-linked continuous glucose monitoring application.” The American journal of emergency medicine (2026). PMID: 42119276 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  138. [138]

    Jiang Y, Cui Y, Su D et al.. “Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42058780 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
  139. [139]

    Wherrett DK, Bundy B, Becker DJ et al.. “Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.” Lancet (London, England) (2011). PMID: 21714999 ↗

    L1RCTCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  140. [140]

    Shao W, Yang K, Lu D et al.. “Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39986331 ↗

    L3OTHERCited in: Severity, Staging and Risk Stratification
  141. [141]

    Antonoglou G, Knuuttila M, Niemelä O et al.. “Serum 1,25(OH)D level increases after elimination of periodontal inflammation in T1DM subjects.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23940127 ↗

    L2OTHERCited in: Severity, Staging and Risk Stratification
  142. [142]

    Mistry S, Gouripeddi R, Raman V et al.. “Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering.” Diabetologia (2022). PMID: 36446887 ↗

    L2OTHERCited in: Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
  143. [143]

    Liu GC, Fang F, Zhou J et al.. “Deletion of p47phox attenuates the progression of diabetic nephropathy and reduces the severity of diabetes in the Akita mouse.” Diabetologia (2012). PMID: 22653270 ↗

    L5OTHERCited in: Severity, Staging and Risk Stratification
  144. [144]

    Broe R, Rasmussen ML, Frydkjaer-Olsen U et al.. “Retinal vascular fractals predict long-term microvascular complications in type 1 diabetes mellitus: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987).” Diabetologia (2014). PMID: 24981770 ↗

    L2OTHERCited in: Severity, Staging and Risk Stratification
  145. [145]

    Yılmaz UC, Kızılay DÖ, Kurt ÖK et al.. “Autoantibody screening in children who are first-degree relatives of individuals with type 1 diabetes in a sibling-dominant cohort in Turkey: a multicentre study on prevalence, determinants and post-screening parent-child anxiety.” Diabetologia (2026). PMID: 42350669 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
  146. [146]

    Idrees H, Memon F, Alam R et al.. “Systematic Review and Meta-Analysis of Insulin Dose and Route of Administration Regimens for Diabetic Ketoacidosis in Children and Adolescents.” Journal of clinical medicine (2025). PMID: 41227190 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  147. [147]

    Fullerton B, Siebenhofer A, Jeitler K et al.. “Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2016). PMID: 27362975 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  148. [148]

    Fullerton B, Jeitler K, Seitz M et al.. “Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2014). PMID: 24526393 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
  149. [149]

    Zhang Q, Saad SH, Zhou H et al.. “Development and validation of an interpretable machine learning model for predicting in-hospital hypoglycemia in adults with type 1 diabetes mellitus: a multicenter retrospective study.” Frontiers in endocrinology (2026). PMID: 42095183 ↗

    L2COHORTCited in: Severity, Staging and Risk Stratification
  150. [150]

    Wang S, Zhang Y, Balati A et al.. “Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39812177 ↗

    L1SR_MA_RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  151. [151]

    Cherney DZ, Reich HN, Scholey JW et al.. “The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes.” Diabetologia (2013). PMID: 23893332 ↗

    L2TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies
  152. [152]

    Marzuillo P, Iafusco D, Zanfardino A et al.. “Acute Kidney Injury and Renal Tubular Damage in Children With Type 1 Diabetes Mellitus Onset.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33595665 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies
  153. [153]

    Dugan CW, Maloney SK, Abramoff KJ et al.. “Effects of Simulated High Altitude on Blood Glucose Levels During Exercise in Individuals With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34935935 ↗

    L1OTHERCited in: Acute Management and Endocrine Emergencies
  154. [154]

    Owens LA, Avalos G, Kirwan B et al.. “ATLANTIC DIP: closing the loop: a change in clinical practice can improve outcomes for women with pregestational diabetes.” Diabetes care (2012). PMID: 22826448 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies
  155. [155]

    Goedendorp MM, Tack CJ, Steggink E et al.. “Chronic fatigue in type 1 diabetes: highly prevalent but not explained by hyperglycemia or glucose variability.” Diabetes care (2013). PMID: 23949561 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies
  156. [156]

    Tsujimoto T, Yamamoto-Honda R, Kajio H et al.. “Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients.” Diabetes care (2013). PMID: 23939540 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies
  157. [157]

    Chantzichristos D, Eliasson B, Johannsson G. “MANAGEMENT OF ENDOCRINE DISEASE Disease burden and treatment challenges in patients with both Addison's disease and type 1 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32299062 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  158. [158]

    Barchetta I, Alessandri C, Bertoccini L et al.. “Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile.” European journal of endocrinology (2015). PMID: 26578639 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  159. [159]

    Ishida-Oku M, Iwase M, Sugitani A et al.. “A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas-kidney transplantation from cardiac death donor.” Diabetologia (2009). PMID: 19911164 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  160. [160]

    Assogba FG, Couchoud C, Hannedouche T et al.. “Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011.” Diabetologia (2014). PMID: 24496924 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  161. [161]

    Beulens JW, Kruidhof JS, Grobbee DE et al.. “Alcohol consumption and risk of microvascular complications in type 1 diabetes patients: the EURODIAB Prospective Complications Study.” Diabetologia (2008). PMID: 18626626 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies
  162. [162]

    Gomes JAF, Vasconcelos AR, Nascimento Júnior JRAD et al.. “Perceived Exertion Is Associated with Cardiovascular Strain but Not Glycemic Response to Gym-Based Exercise in Adults with Type 1 Diabetes: An Exploratory Randomized Crossover Trial.” International journal of environmental research and public health (2026). PMID: 42354343 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  163. [163]

    Mitchell S, Patwardhan K, Lucocq J et al.. “Metabolic and bariatric surgery for patients with obesity type 1 diabetes mellitus: A comprehensive updated systematic review and meta-analysis.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41904365 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies
  164. [164]

    Guo Y, Mei Y, Bongaerts B et al.. “(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis.” The Cochrane database of systematic reviews (2026). PMID: 42318853 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies
  165. [165]

    Skott E, Cai W, Stiernborg M et al.. “Associations of prenatal exposure to maternal autoimmune disorders with a wide spectrum of psychiatric and neurodevelopmental disorders in offspring-a nationwide cohort study.” Human reproduction open (2026). PMID: 42077501 ↗

    L2COHORTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  166. [166]

    Kim JY, Kim S, Kim JH. “Association between Continuous Glucose Monitoring and Risk of Acute Diabetes-Related Complications in Pediatric Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2026). PMID: 42014052 ↗

    L2COHORTCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  167. [167]

    Kang YM, Giugliano RP, Ran X et al.. “Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.” Diabetes care (2025). PMID: 40544474 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  168. [168]

    Ruiz de Adana MS, Alhambra-Expósito MR, Muñoz-Garach A et al.. “Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study.” Diabetes care (2019). PMID: 31831473 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  169. [169]

    Porcellati F, Lucidi P, Candeloro P et al.. “Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.” Diabetes care (2018). PMID: 30305345 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  170. [170]

    Rys PM, Ludwig-Slomczynska AH, Cyganek K et al.. “Continuous subcutaneous insulin infusion vs multiple daily injections in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials and observational studies.” European journal of endocrinology (2018). PMID: 29545258 ↗

    L1SR_MA_RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  171. [171]

    Ocheltree SM, Hompesch M, Wondmagegnehu ET et al.. “Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.” European journal of endocrinology (2010). PMID: 20508081 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  172. [172]

    Del Favero S, Bruttomesso D, Di Palma F et al.. “First use of model predictive control in outpatient wearable artificial pancreas.” Diabetes care (2014). PMID: 24757228 ↗

    L4TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  173. [173]

    Park J, Ntelis S, Yunasan E et al.. “Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37561012 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  174. [174]

    Bergenstal RM, Tamborlane WV, Ahmann A et al.. “Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.” The New England journal of medicine (2010). PMID: 20587585 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  175. [175]

    Russell SJ, El-Khatib FH, Sinha M et al.. “Outpatient glycemic control with a bionic pancreas in type 1 diabetes.” The New England journal of medicine (2014). PMID: 24931572 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  176. [176]

    Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al.. “Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.” The New England journal of medicine (2009). PMID: 19940299 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  177. [177]

    Osipova J, Fischer DC, Dangwal S et al.. “Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24937532 ↗

    L4COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  178. [178]

    Heller S, Buse J, Fisher M et al.. “Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.” Lancet (London, England) (2012). PMID: 22521071 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  179. [179]

    Beam CA, MacCallum C, Herold KC et al.. “GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.” Diabetologia (2016). PMID: 27704166 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  180. [180]

    Thorius IH, Husemoen LLN, Nordsborg RB et al.. “Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study.” Diabetologia (2023). PMID: 36640191 ↗

    L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  181. [181]

    Al-Naseem AO, Attia A, Gonnah AR et al.. “Pancreas transplantation today: quo vadis?” European journal of endocrinology (2023). PMID: 36929837 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  182. [182]

    Wiegand S, Raile K, Reinehr T et al.. “Daily insulin requirement of children and adolescents with type 1 diabetes: effect of age, gender, body mass index and mode of therapy.” European journal of endocrinology (2008). PMID: 18362302 ↗

    L2OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  183. [183]

    Moser O, Becker U, van den Boom L et al.. “[Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].” Wiener klinische Wochenschrift (2026). PMID: 42162485 ↗

    L1GUIDELINECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
  184. [184]

    Amaral R, Costa B, Penedones A et al.. “Efficacy and Safety of Once-Weekly and Once-Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of Clinical Trials.” Diabetes, obesity & metabolism (2026). PMID: 42225295 ↗

    L1TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  185. [185]

    Bellin MD, Dunn TB. “Transplant strategies for type 1 diabetes: whole pancreas, islet and porcine beta cell therapies.” Diabetologia (2020). PMID: 32894315 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  186. [186]

    Tamahane V, Shah N, Kajale N et al.. “Effect of prebiotic intervention on glycemic control and gut microbiome profile in Indian children with type 1 diabetes mellitus (T1DM): a pilot randomised control trial.” Endocrine (2026). PMID: 42165942 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  187. [187]

    Campbell F, Biggs K, Aldiss SK et al.. “Transition of care for adolescents from paediatric services to adult health services.” The Cochrane database of systematic reviews (2016). PMID: 27128768 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  188. [188]

    Abdelghaffar S, Attia AM. “Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.” The Cochrane database of systematic reviews (2009). PMID: 19160294 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  189. [189]

    Hemmingsen B, Metzendorf MI, Richter B. “(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2021). PMID: 33662147 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  190. [190]

    Vardi M, Jacobson E, Nini A et al.. “Intermediate acting versus long acting insulin for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2008). PMID: 18646147 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  191. [191]

    Misso ML, Egberts KJ, Page M et al.. “Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2010). PMID: 20091571 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  192. [192]

    Copur S, Mizrak B, Ozbek L et al.. “Once-Weekly Subcutaneous Insulin Efsitora for the Management of Diabetes Mellitus: A Systematic Review and Meta-Analysis Study.” Medeniyet medical journal (2026). PMID: 42383405 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  193. [193]

    Toghi-Eshghi SR, Yardley JE. “Morning (Fasting) vs Afternoon Resistance Exercise in Individuals With Type 1 Diabetes: A Randomized Crossover Study.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31211392 ↗

    L1RCTCited in: History and Evolution of Treatment
  194. [194]

    Parthasarathy G, Kudva YC, Low PA et al.. “Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial.” The Journal of clinical endocrinology and metabolism (2017). PMID: 27880079 ↗

    L1RCTCited in: History and Evolution of Treatment
  195. [195]

    Haider DG, Pleiner J, Francesconi M et al.. “Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16895956 ↗

    L4RCTCited in: History and Evolution of Treatment
  196. [196]

    Sarem Z, Bumke-Vogt C, Mahmoud AM et al.. “Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28911141 ↗

    L1RCTCited in: History and Evolution of Treatment
  197. [197]

    Crowne EC, Samra JS, Cheetham T et al.. “The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2001). PMID: 11502796 ↗

    L1RCTCited in: History and Evolution of Treatment
  198. [198]

    Griffen SC, Oostema K, Stanhope KL et al.. “Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2005). PMID: 16317063 ↗

    L1RCTCited in: History and Evolution of Treatment
  199. [199]

    Herold KC, Hagopian W, Auger JA et al.. “Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037148 ↗

    L1RCTCited in: History and Evolution of Treatment
  200. [200]

    . “Effects of insulin in relatives of patients with type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037147 ↗

    L1RCTCited in: History and Evolution of Treatment
  201. [201]

    Nathan DM, Lachin J, Cleary P et al.. “Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.” The New England journal of medicine (2003). PMID: 12788993 ↗

    L2RCTCited in: History and Evolution of Treatment
  202. [202]

    Keymeulen B, Vandemeulebroucke E, Ziegler AG et al.. “Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.” The New England journal of medicine (2005). PMID: 15972866 ↗

    L1RCTCited in: History and Evolution of Treatment
  203. [203]

    Skyler JS, Cefalu WT, Kourides IA et al.. “Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study.” Lancet (London, England) (2001). PMID: 11210993 ↗

    L1RCTCited in: History and Evolution of Treatment
  204. [204]

    Shapiro AM, Lakey JR, Ryan EA et al.. “Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.” The New England journal of medicine (2000). PMID: 10911004 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  205. [205]

    Bally L, Zueger T, Buehler T et al.. “Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study.” Diabetologia (2016). PMID: 26739816 ↗

    L1RCTCited in: History and Evolution of Treatment
  206. [206]

    Ang M, Meyer C, Brendel MD et al.. “Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes.” Diabetologia (2013). PMID: 24305963 ↗

    L3RCTCited in: History and Evolution of Treatment
  207. [207]

    Garg S, Rosenstock J, Silverman BL et al.. “Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.” Diabetologia (2006). PMID: 16506054 ↗

    L1RCTCited in: History and Evolution of Treatment
  208. [208]

    Davison GW, Ashton T, George L et al.. “Molecular detection of exercise-induced free radicals following ascorbate prophylaxis in type 1 diabetes mellitus: a randomised controlled trial.” Diabetologia (2008). PMID: 18769906 ↗

    L1RCTCited in: History and Evolution of Treatment
  209. [209]

    Jenni S, Oetliker C, Allemann S et al.. “Fuel metabolism during exercise in euglycaemia and hyperglycaemia in patients with type 1 diabetes mellitus--a prospective single-blinded randomised crossover trial.” Diabetologia (2008). PMID: 18512043 ↗

    L1RCTCited in: History and Evolution of Treatment
  210. [210]

    Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S et al.. “Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus.” Lancet (London, England) (2001). PMID: 11418149 ↗

    L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  211. [211]

    Edwards K, Li X, Lingvay I. “Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36268825 ↗

    L4OTHERCited in: History and Evolution of Treatment
  212. [212]

    Galassetti P, Tate D, Neill RA et al.. “Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2002). PMID: 12414885 ↗

    L4OTHERCited in: History and Evolution of Treatment
  213. [213]

    Kudva YC, Reynolds C, O'Brien T et al.. “"Diabetic mastopathy," or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes.” Diabetes care (2002). PMID: 11772912 ↗

    L3OTHERCited in: History and Evolution of Treatment
  214. [214]

    Lu CL, Shen HN, Hu SC et al.. “A Population-Based Study of All-Cause Mortality and Cardiovascular Disease in Association With Prior History of Hypoglycemia Among Patients With Type 1 Diabetes.” Diabetes care (2016). PMID: 27385329 ↗

    L3OTHERCited in: History and Evolution of Treatment, Complications and Long-term Sequelae
  215. [215]

    Cabrera SM, Chen YG, Hagopian WA et al.. “Blood-based signatures in type 1 diabetes.” Diabetologia (2015). PMID: 26699650 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention
  216. [216]

    Zhang Q, Zhou H, Lin R et al.. “Risk factors for hypoglycaemia in adults with type 1 diabetes: a systematic review and meta-analysis.” BMC endocrine disorders (2025). PMID: 41449374 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  217. [217]

    Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗

    L1GUIDELINECited in: History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  218. [218]

    Tang D, Gao X, Zhu M et al.. “Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs.” Clinical pharmacokinetics (2026). PMID: 41489799 ↗

    L4RCTCited in: History and Evolution of Treatment
  219. [219]

    Drai R, Galstyan G, Karonova T et al.. “Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial.” Diabetes, obesity & metabolism (2025). PMID: 41366610 ↗

    L1RCTCited in: History and Evolution of Treatment
  220. [220]

    Almutairi MNASF. “Neurodevelopmental effects of severe hypoglycemia in children with type 1 diabetes: a systematic review.” Frontiers in pediatrics (2026). PMID: 41660395 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  221. [221]

    Aoki TT, Benbarka MM, Okimura MC et al.. “Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus.” Lancet (London, England) (1993). PMID: 8102666 ↗

    L4OTHERCited in: History and Evolution of Treatment
  222. [222]

    Kugathasan L, Katz A, Muskiet MHA et al.. “Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.” Kidney international reports (2026). PMID: 42205183 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  223. [223]

    Pham-Dobor G, Kaltenecker P, Temesfoi V et al.. “Systematic Analysis and Network Mapping of Disease Associations in Autoimmune Polyglandular Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39378147 ↗

    L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  224. [224]

    Łebkowska A, Adamska A, Krentowska A et al.. “The Influence of Prepubertal Onset of Type 1 Diabetes and Age of Menarche on Polycystic Ovary Syndrome Diagnosis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33537700 ↗

    L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  225. [225]

    van Dijk M, Donga E, van Dijk JG et al.. “Disturbed subjective sleep characteristics in adult patients with long-standing type 1 diabetes mellitus.” Diabetologia (2011). PMID: 21573904 ↗

    L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  226. [226]

    Xiao YL, Jia YQ, Gu LQ et al.. “Prevalence of Celiac Disease in China Among High-Risk Populations: A Systematic Review and Meta-Analysis.” Journal of digestive diseases (2025). PMID: 41183986 ↗

    L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  227. [227]

    Fagerholm E, Ahlqvist E, Forsblom C et al.. “SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes.” Diabetologia (2012). PMID: 22643932 ↗

    L3SR_OBSCited in: Complications and Long-term Sequelae
  228. [228]

    González-Clemente JM, Vilardell C, Broch M et al.. “Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes.” European journal of endocrinology (2007). PMID: 17609399 ↗

    L4OTHERCited in: Complications and Long-term Sequelae
  229. [229]

    Głowińska-Olszewska B, Moniuszko M, Hryniewicz A et al.. “Relationship between circulating endothelial progenitor cells and endothelial dysfunction in children with type 1 diabetes: a novel paradigm of early atherosclerosis in high-risk young patients.” European journal of endocrinology (2013). PMID: 23111589 ↗

    L3OTHERCited in: Complications and Long-term Sequelae
  230. [230]

    Nathan DM. “Realising the long-term promise of insulin therapy: the DCCT/EDIC study.” Diabetologia (2021). PMID: 33550441 ↗

    L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
  231. [231]

    Chimen M, Kennedy A, Nirantharakumar K et al.. “What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review.” Diabetologia (2011). PMID: 22189486 ↗

    L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
  232. [232]

    Colombo M, McGurnaghan SJ, Bell S et al.. “Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus.” Diabetologia (2019). PMID: 31807796 ↗

    L2OTHERCited in: Complications and Long-term Sequelae
  233. [233]

    Cakmak Demir S, Batman A, Yazici D et al.. “Association of High-Risk Obstructive Sleep Apnea with Microvascular Complications in Adults with Type 1 Diabetes Mellitus: A Case-Control Study.” Journal of clinical medicine (2026). PMID: 42074704 ↗

    L3CASE_CONTROLCited in: Complications and Long-term Sequelae
  234. [234]

    Rodrigues F, White M, O'Connell MA. “Hyperlipidaemia in youth with type 1 diabetes: Are current guidelines clinically useful?” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42387672 ↗

    L4OTHERCited in: Complications and Long-term Sequelae
  235. [235]

    Tentolouris A, Popovic DS, Liarakos AL et al.. “GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.” Diabetes, obesity & metabolism (2026). PMID: 42380553 ↗

    L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
  236. [236]

    García-Poblet M, Martínez-Sanz JM, Alberola-Chazarra MA et al.. “Phase angle and triglyceride-glucose index as biomarkers of glycemic control, body composition and cardiovascular risk in adolescents with type 1 diabetes: a cross-sectional study.” Journal of endocrinological investigation (2026). PMID: 42371339 ↗

    L4OTHERCited in: Complications and Long-term Sequelae
  237. [237]

    Buschur EO, Polsky S. “Type 1 Diabetes: Management in Women From Preconception to Postpartum.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33331893 ↗

    L5SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention
  238. [238]

    Basu A, Alaupovic P, Wu M et al.. “Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22438226 ↗

    L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention
  239. [239]

    Kim KM, Kim KJ, Han K et al.. “Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37850407 ↗

    L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention
  240. [240]

    Castellaneta S, Piccinno E, Oliva M et al.. “High rate of spontaneous normalization of celiac serology in a cohort of 446 children with type 1 diabetes: a prospective study.” Diabetes care (2015). PMID: 25784659 ↗

    L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention
  241. [241]

    Allen LA, Cannings-John RL, Evans A et al.. “Pregnancy in teenagers diagnosed with type 1 diabetes mellitus in childhood: a national population-based e-cohort study.” Diabetologia (2019). PMID: 31863141 ↗

    L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention
  242. [242]

    Tosur M, Geyer SM, Rodriguez H et al.. “Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk.” Diabetologia (2018). PMID: 29931415 ↗

    L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention
  243. [243]

    García-Patterson A, Gich I, Amini SB et al.. “Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction.” Diabetologia (2009). PMID: 20013109 ↗

    L4OTHERCited in: Prognosis, Natural History, Special Populations and Prevention

Revision History

All updates applied to this page

Loading revisions…